The Ras/mitogen-activated protein kinase (MAPK) signalling cascade regulates various biological functions, including cell growth, proliferation and survival. As such, this pathway is often deregulated in cancer, including melanomas, which frequently harbour activating mutations in the NRAS and BRAF oncogenes. Hyperactive MAPK signalling is known to promote protein synthesis, but the mechanisms by which this occurs remain poorly understood. Here, we show that expression of oncogenic forms of Ras and Raf promotes the constitutive activation of the mammalian target of rapamycin (mTOR). Using pharmacological inhibitors and RNA interference, we find that the MAPK-activated protein kinase RSK (p90 ribosomal S6 kinase) is partly required for these effects. Using melanoma cell lines carrying activating BRAF mutations, we show that ERK/RSK signalling regulates assembly of the translation initiation complex and polysome formation, as well as the translation of growth-related messenger RNAs containing a 5 0 -terminal oligopyrimidine (TOP) motif. Accordingly, we find that RSK inhibition abrogates tumour growth in mice. Our findings indicate that RSK may be a valuable therapeutic target for the treatment of tumours characterized by deregulated MAPK signalling, such as melanoma.
INTRODUCTION
The Ras/mitogen-activated protein kinase (MAPK) signalling cascade regulates a wide range of cellular functions, including cell growth, proliferation and survival. 1, 2 In this pathway, ligand binding to growth factor receptors leads to activation of the small GTPase Ras, which allows membrane recruitment and activation of the Raf protein kinases. Once activated, Raf phosphorylates and activates MEK1/2, which are dual-specificity kinases capable of phosphorylating and activating the MAPKs ERK1/2. Hyperactivation of the MAPK pathway is a highly prevalent event in human cancer and usually results from aberrant activation of receptor tyrosine kinases or by gain-of-function mutations in Ras or Raf isoforms. 3 One prominent example is melanoma, where activating mutations in BRAF or NRAS (in B50% and B15% of cases, respectively) are the earliest genotypic changes observed. [3] [4] [5] More than 90% of BRAF mutations encode a protein harbouring the V600E mutation, which constitutively activates ERK1/2 signalling. 6 Malignant melanoma is highly resistant to conventional chemotherapy, 7 but recently developed therapies that target components of the MAPK pathway have demonstrated survival advantage in patients with BRAF-mutated melanoma. 8 The Ras/MAPK pathway promotes cell growth and proliferation by controlling the activity of various transcription factors and cell cycle regulators. 9 In addition, this pathway was shown to stimulate protein synthesis, 10, 11 but the molecular mechanisms involved in this process remain poorly understood. The MAPK-activated protein kinases MNK1/2 were found to phosphorylate the translation initiation factor eIF4E, 12, 13 providing a potential mechanism by which MAPK signalling regulates messenger RNA (mRNA) translation (reviewed in 14, 15 ). However, the MNKs have been shown to be dispensable for global protein synthesis, 16 and may only regulate the translation of a specific subset of mRNAs. 17 The p90 ribosomal S6 kinase (RSK) family comprises four protein kinases that are directly phosphorylated and activated by ERK1/ 2. 18 RSK regulates various substrates involved in cell proliferation and survival, [19] [20] [21] and was found to be hyperactivated in several types of cancer, 22 including melanoma. 23 Increasing evidence indicates that ERK/RSK signalling participates in the regulation of the mammalian target of rapamycin (mTOR), 24, 25 providing an additional mechanism by which MAPK signalling regulates the translational machinery. 26 mTOR is an evolutionarily conserved Ser/Thr kinase that has essential roles in the regulation of cell growth.
27,28 mTOR associates with different protein partners to form two functionally distinct complexes, the rapamycin-sensitive and -insensitive mTOR complex (mTORC) 1 and 2, respectively. 3, 29, 30 mTORC1 positively regulates mRNA translation by stimulating two main translational regulators, the eukaryotic translation initiation factor 4E (eIF4E) and the p70 ribosomal S6 kinases (S6K1 and S6K2). 26, 31 While eIF4E promotes recruitment of the ribosome at the 5 0 cap of mRNAs, 32 activated S6Ks phosphorylate proteins involved in pre-mRNA processing and ribosome biogenesis, including the 40S ribosomal protein (rp) S6.
33 mTORC1 is 1 frequently deregulated in human cancer and its activation is often linked with mutations in components of the phosphoinositide-3 kinase (PI3K) pathway. 34 In melanoma, increased mTORC1 activity has been observed in B70% of tumours, 35 but it is currently unknown whether ERK/RSK signalling contributes to this deregulation.
In this study, we demonstrate that oncogenic activation of the MAPK pathway promotes constitutive mTORC1 activity and function. More specifically, we identify RSK as a key MAPK substrate involved in the regulation of mTORC1 in melanoma. Inhibition of RSK expression or activity results in decreased mTORC1 activity and function, as well as reduced melanoma cell and tumour growth. Together, these data suggest that RSK may be a valuable therapeutic target for the treatment of metastatic melanoma.
RESULTS
Oncogenic Ras and Raf promote mTORC1 signalling in an ERK/RSK-dependent manner To examine the contribution of oncogenic MAPK signalling in the regulation of mTORC1, we generated stable HEK293 cell lines expressing activated alleles of MEK1 (MEK-DD), H-Ras (G12V) or B-Raf (V600E) (Figure 1a ). These cells were starved of serum overnight to reduce basal mTORC1 activity resulting from growth factors present in serum. To monitor mTORC1 activity, we have quantified several established mTORC1-dependent events, such as S6K1 phosphorylation at its mTORC1-regulated site (Thr389), rpS6 phosphorylation at S6K1-specific residues (Ser240/244), as well as the kinase activity of immunoprecipitated endogenous S6K1. Using these three approaches, we found that all three cell lines displayed constitutively high levels of mTORC1 activity (Figure 1b , lane 1 of each panel), which were sensitive to rapamycin treatment (Figure 1b , lane 6 of each panel). To characterize the involvement of the MAPK pathway, cells were pre-treated with inhibitors of MEK1/2 (U0126 or PD184352) or RSK (BI-D1870 or SL0101) for 1 h before being collected. These inhibitors resulted in a robust decrease in mTORC1 activity (Figure 1b) , suggesting that oncogenic ERK/RSK signalling contributes significantly to the regulation of mTORC1 activity. To measure mTORC1-dependent functions, we tested the effect of MEK1/2 and RSK inhibitors on global protein synthesis. As expected, we found that oncogenic activation of the MAPK pathway increased tritiated leucine incorporation compared with control cells (Figure 1c) . Interestingly, we found that inhibition of ERK/RSK signalling significantly suppressed global protein synthesis in all three cell lines Figure 1 . Oncogenic RAS and RAF promote mTORC1 signalling in a RSK-dependent manner. (a) HEK293 cells stably expressing constitutively activated MEK1 (MEK-DD), Ras (G12V) or Raf (V600E) were serum-starved overnight, and analysed for ERK and RSK phosphorylation by immunoblotting. Immunoprecipitated RSK1 kinase activity was assayed using GST-rpS6 as substrate, in the presence of g[ Figure S1A) . Interestingly, these cells also display constitutively high mTORC1 activity compared with serum-starved or insulin-treated normal human melanocytes (Figure 2b ), suggesting the involvement of the MAPK pathway. Consistent with this, we found that mTORC1 activity in melanoma cells was highly sensitive to inhibitors of ERK/RSK signalling (Figures 2c and d) . This effect was not due to a modulation of the PI3K/Akt pathway, as we did not detect variations in Akt phosphorylation in serum-starved A375 cells treated with inhibitors at the same concentration (Supplementary Figure  S1B) . Whereas cells harbouring activating mutations in BRAF and NRAS were all sensitive to the RSK inhibitors, it is noteworthy that MEK1/2 inhibition resulted in a weaker inhibitory effect in NRAS cells.
To validate the requirement for RSK activity, we used RNA interference to specifically silence RSK expression in melanoma cells. First, we determined the expression levels of all RSK isoforms and found that RSK1 and RSK2 were the most abundant isoforms at the mRNA level (Figure 3a) . To reduce RSK expression, we used two complementary approaches using small interfering RNA (siRNA)-or short hairpin (shRNA)-mediated RNA interference. Using these approaches, we found that transient knockdown of RSK1/2 expression in Colo829 cells resulted in a significant inhibition of mTORC1 activity (Supplementary Figure S2) . The role of the MAPK pathway was also verified using siRNA duplexes targeting ERK1/2 expression, which resulted in a similar inhibitory effect (Supplementary Figure S2) . We also generated A375 and WM1361 stable cell lines expressing shRNAs targeting RSK1 and RSK2. When these cells were serum-starved overnight, we found that RSK knockdown significantly decreased mTORC1 activity (Figure 3b ). Similar results were obtained when depleting RSK in other melanoma cell lines, such as WM852 and SK-MEL-2 (data not shown). Together, these results demonstrate that endogenous RSK contributes to the regulation of mTORC1 signalling in melanoma cells.
ERK/RSK signalling promotes mTORC1-mediated eIF4F assembly and mRNA translation in melanoma Next, we investigated whether ERK/RSK signalling regulates mTORC1-dependent protein synthesis in melanoma. First, cells were serum-starved and treated with MEK1/2 or RSK inhibitors before measuring tritiated leucine incorporation. Consistent with results from HEK293 cells, we found that ERK/RSK signalling was required for global protein synthesis in the four melanoma cell lines tested ( Figure 4a ). To determine whether ERK/RSK signalling regulates mRNA translation, we examined polysome assembly using sucrose gradient sedimentation. Notably, we found that treatment of Colo829 cells with MEK1/2 or RSK inhibitors significantly decreased polysome assembly and proportionally increased the number of free ribosomes ( Figure 4b ). Indeed, we found that inhibitor treatment reduced the polysome/subpolysome (P/S) ratio by B65% compared with vehicle-treated cells ( Figure 4b and Supplementary Figure S3 ), suggesting that ERK/RSK signalling has a major role in regulating mRNA translation in melanoma. mTORC1 promotes mRNA translation by phosphorylating and inactivating the eIF4E-binding proteins (4E-BPs), resulting in their dissociation from eIF4E and assembly of the eIF4F complex (eIF4E, eIF4G and eIF4A). As with S6K1, we found that melanoma cells display high levels of 4E-BP1 phosphorylation (Figures 2b and 4c), which reflects the constitutively high mTORC1 activity found in these cells ( Figure 2 ). To determine the role of ERK/RSK signalling in eIF4F assembly, we used 7-methylguanosineconjugated sepharose beads to purify eIF4E and associated proteins from Colo829 cells. Interestingly, we found that treatment of cells with MEK1/2 or RSK inhibitors significantly increased the association of hypophosphorylated 4E-BP1 to eIF4E (Figure 4c ), suggesting that oncogenic ERK/RSK signalling promotes mTORC1-dependent phosphorylation of 4E-BP1 in melanoma cells. We observed that MEK1/2 and RSK inhibition dramatically decreased 4E-BP1 phosphorylation on three sites (Thr37/Thr46/Ser65) known to be regulated by mTORC1 (Figure 4c ), suggesting that RSK promotes eIF4F formation through the control of mTORC1-dependent 4E-BP1 phosphorylation. Consistent with this, we found that MEK1/2 and RSK inhibition robustly reduced eIF4G recruitment to eIF4E. As expected, inhibition of mTOR using KU-0063794 also reduced eIF4F complex formation, and as shown by others, 36 we found that rapamycin treatment was less efficient than KU-0063794 to inhibit eIF4F formation (Figure 4c ). Together, these data demonstrate that ERK/RSK signalling has an important role in mTORC1-dependent translation initiation in melanoma cells.
ERK/RSK signalling promotes translation of growth-related mRNAs in melanoma Next, we investigated the type of transcripts that were regulated by ERK/RSK signalling in melanoma cells using a global microarray-based approach. We compared total and polysome-bound RNAs to globally identify mRNAs that are actively being translated (polysomal mRNA) and normalize their levels to their overall abundance in the cell (total mRNA). Total and polysomal RNAs were extracted from Colo829 cells treated with MEK1/2 (PD184352), RSK (BI-D1870) or mTORC1 (KU-0063794 and rapamycin) inhibitors, and hybridized to human NimbleGen 60-mer oligonucleotides arrays. Cellular treatments were limited to 1 h to minimize potential transcriptional effects of these drugs. Resulting data were analysed and compared using several bioinformatics approaches (as described in Materials and Methods), and a statistically significant (Po0.05) cutoff value of 1.5-fold (log2-coefficient ¼ À 0.58) decrease in the relative abundance of total or polysomal mRNA upon inhibitor treatment was used to designate specific regulation. Overall, the number of downregulated genes upon inhibition of the ERK/RSK pathway was greater in the polysomal RNA fraction compared with total RNAs (Supplementary Figure S4A) , consistent with the idea that ERK/RSK signalling regulates mRNA translation ( Figure 4 ). As expected, we observed similar effects when blocking mTORC1 activity for one hour (Supplementary Figure S4A) . Overall, we identified 577 genes that displayed at least a 1.5-fold decrease in the relative amount of polysomal mRNA as a function of MAPK or mTORC1 inhibition (Supplementary Dataset S1). The vast majority of these genes (377) were regulated by both pathways, while 31 and 88 genes were specifically regulated by the MAPK and mTOR pathways, respectively (Figure 5a ). These results strongly support the notion that ERK/RSK signalling controls the translation of mTORC1-dependent mRNAs, and gene function enrichment analysis revealed that these mRNAs belong to growth-related biological functions, such as translation initiation, elongation, cellular response to stress or cell cycle (Figure 5b) .
A search for genes having similar response patterns to MAPK and mTORC1 signalling was performed using K-Means clustering. Among identified clusters, two groups of mRNAs whose translation are repressed upon inhibitor treatment were identified (Figure 5c and Supplementary Figure S4B) . Enrichment analysis identified one predominant biological group in the cluster, namely, protein synthesis (Figure 5e ). Fifteen different ribosomal proteins, one translation initiation and two elongation factors were present within these groups (Figures 5c and d and Supplementary Figure S4C) , suggesting that many ERK/RSKregulated mRNAs are involved in ribosome biogenesis or encode components of the translational machinery. A common feature of RNAs encoding components of the translational machinery is the presence in their 5 0 -untranslated region of a terminal oligopyrimidine motif that is known to be associated with mTORC1-dependent translation regulation. 37 Strikingly, one cluster was found to be significantly enriched in mRNAs that have been previously shown to contain a 5 0 -oligopyrimidine motif (22 out of 50 mRNAs, Fisher's exact test P-value ¼ 1.555e-12). 38 Many of these mRNAs have previously been shown to be regulated by mTOR and/or rapamycin treatment, such as eEF1b and Rpl12. 39 Together, these data highly suggest that ERK/RSK signalling converges on mTORC1 to regulate the translation of mRNAs involved in melanoma cell growth.
RSK is required for efficient melanoma cell proliferation and tumour development in mice To determine the biological function of ERK/RSK signalling in melanoma, we next evaluated the impact of knocking down RSK1/2 on melanoma cell proliferation. Depletion of RSK1/2 by shRNA-mediated RNA interference in serum-growing Colo829 and A375 cells resulted in a significant decrease in proliferation rates, as shown by measuring global metabolic activity (Figure 6a) or . Cell extracts were size-fractionated by centrifugation through sucrose gradients (20-50%). The absorbance of polysomes (P) and subpolysomal (S) particles was continuously monitored at 260 nm. Representative A 260 nm traces are shown (n ¼ 3). The area under the curves was calculated and the P/S ratio refers to the percentage of ribosomes engaged in translation. The data are normalized to P/S ratio of control condition (dimethylsulphoxide) and presented as a mean±s.e. (n ¼ 3). (c) Association of 4E-BP1 and eIF4G to the 7-methylguanosine cap complex was monitored by immunoblotting 7-methylguanosine precipitates from serum-starved Colo829 cells, pre-treated with the indicated inhibitors for 60 min. Equal levels between precipitates were monitored through analysis of eIF4E. Phosphorylation and total protein level of endogenous 4E-BP1 and ERK1/2 were monitored by immunoblotting.
using cell counts (Figure 6b ). Because RSK was previously shown to inhibit apoptotic cell death, 21, 40 we determined whether RSK1/2 knockdown increased Annexin V binding. Our results indicate that the number of apoptotic cells was significantly increased by RSK knockdown (Figure 6c ), but that these changes could not entirely explain the large reduction in cell proliferation (Figures 6a and b) . Using pharmacological inhibitors, we also found that inhibition of ERK/RSK signalling reduced melanoma cell proliferation to levels similar to cells treated with mTOR inhibitors (Figure 6d ), and again, these treatments did not significantly increased apoptosis of melanoma cells (Figure 6e) .
Finally, we investigated the role of RSK in melanoma tumour growth using a xenotransplantation assay in nude mice. For this, A375 or Colo829 cells were infected with lentiviruses expressing RSK1/2 shRNAs, and populations of transduced cells (2 Â 10 6 cells) were injected subcutaneously in the flanks of nude mice. As shown in Figures 6f and g, A375 and Colo829 cells expressing a control shRNA rapidly formed tumours in mice, reaching 0.5 cm 3 within B30-50 days of injection. In sharp contrast, depletion of RSK1/2 almost completely inhibited tumour formation from A375 and Colo829 cells, indicating that RSK is essential for melanoma tumour growth in vivo. We monitored RSK1/2 expression in xenografts from A375 cells obtained 2 months post-injection (Figure 6f) , and found that these tumours recovered RSK expression to almost wild-type levels. Together, our data indicate that ERK/RSK signalling contributes to the constitutively high mTORC1 activity in melanoma cells, and that RSK inhibition abrogates tumour development in mice.
DISCUSSION
The data presented here demonstrate that oncogenic MAPK signalling promotes constitutive mTORC1 activation and downstream signalling to its main targets, S6K1 and 4E-BP1 ( Figures  1-4) . Further, our results indicate that the ERK1/2-activated protein kinase RSK has an important role in this process, as RSK inhibitors and RNA interference strongly reduced mTORC1 activity in melanoma (Figures 2-4) . Consistently, we found that ERK/RSK signalling regulates the translation of growth-related mRNAs also controlled by the mTOR pathway ( Figure 5 ), supporting the notion that oncogenic ERK/RSK signalling promotes mTORC1-dependent functions. RSK depletion was found to inhibit melanoma cell proliferation and tumour growth (Figure 6 ), indicating that melanoma cells are highly dependent on ERK/RSK signalling for their growth and proliferation.
Translational regulation has a pivotal role in tumour formation and metastasis. 41, 42 Accordingly, our data indicate that RSK controls melanoma cell growth by modulating the phosphorylation status of important components of the translational machinery. Particularly, the inhibitory activity of 4E-BP1 was found to be highly dependent on ERK/RSK signalling, as inhibition of MEK1/2 and RSK dramatically decreased eIF4F complex formation and polysome formation. These results suggest that 4E-BP1 has an important role in mediating MAPK-dependent melanoma cell growth. This is supported by observations that depletion of Raptor in melanoma cells is lethal (data not shown), and by studies showing that tumours in which 4E-BP1 expression is reduced are less addicted to oncogenic MAPK signalling. 43 Our findings are in a good agreement with recent studies demonstrating that 4E-BP1 is a major integrator of oncogenic signalling pathways 44 and that mTORC1-dependent cell proliferation is mediated by the 4E-BPs. 45 Although we have shown that ERK/RSK signalling regulates cell growth via mTORC1, we cannot exclude additional modes of translational regulation. Indeed, rapamycin was found to be less effective than RSK inhibitors in reducing global protein synthesis (Figures 4 and 6) , suggesting that ERK/RSK signalling regulates additional proteins involved in mRNA translation. Consistent with this, RSK was previously shown to phosphorylate the translation initiation factor eIF4B and thereby stimulate its recruitment to the translation initiation complex. 46 The ribosomal protein S6 has also been shown to be directly phosphorylated by RSK at Ser235/236, 47 but the exact outcome of this phosphorylation event remains elusive. Therefore, ERK/RSK signalling seems to participate at several levels of translational control, which may explain the acute dependency of melanoma cells to ERK/RSK activity. Consistent with these findings, ERK and RSK were recently shown to regulate LKB1, 48 a tumour suppressor protein that is involved in the activation of the AMP-activated protein kinase. ERK-and RSKmediated phosphorylation of LKB1 was shown to be important for cell proliferation, 48 suggesting that several ERK/RSK-dependent mechanisms may contribute to the regulation of melanoma growth.
Our data demonstrate a molecular link between oncogenic MAPK signalling and mTOR-dependent growth in melanoma, and indicate that RSK may be a valuable therapeutic target for the treatment of metastatic melanomas, as well as other cancer types characterized by the hyperactivation of the MAPK pathway. RSK inhibitors could also be used in combination with drugs that target the PI3K pathway, as was done with MEK1/2 inhibitors, 49 which may inhibit mTORC1 more efficiently in tumours that also display activating mutations in PI3K pathway components.
MATERIALS AND METHODS

Cell culture and treatments
The cell lines used in this study were purchased from ATCC (Manassas, VA, USA; A375, Colo829 and SK-MEL-2) or Coriell (Camden, NJ, USA; WM1361 and WM852). The human epidermal melanocytic (105-25N) cell line was purchased from Cell Applications (San Diego, CA, USA) and grown in Melanocyte Growth Medium (135-500, Cell Applications). HEK293, A375 and SK-MEL-2 cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS) and antibiotics. Colo829 cells were grown in RPMI medium supplemented with 10% FBS and antibiotics. WM1361 and WM852 were maintained in (4:1) MCDB 153:Leibovitz L-15 media supplemented with 2% FBS, 1.69 mM CaCl 2 , 5 mg/ml insulin and antibiotics. HEK293 stable cell lines were generated using pBabe-puro-derived retroviral particles, and expressing cells were selected using puromycin (2 mg/ml). Cells were serum-starved overnight and treated with agonists/ inhibitors as indicated. Starved cells were pre-treated with U0126 (20 mM), PD184352 (10 mM), SL0101 (50 mM), BI-D1870 (10 mM), KU-0063794 (5 mM) or rapamycin (25 nM, except when indicated) (Biomol, Plymouth Meeting, PA, USA).
Antibodies
Antibodies targeted against phospho-rpS6 (Ser240/244 and Ser235/236), phospho-Akt (Ser473), ERK1/2, phospho-4EBP1 (Thr37/46), S6K1 and phospho-S6K1 (Thr389) were purchased from Cell Signaling Technologies (Beverly, MA, USA). Anti-phospho-ERK1/2 monoclonal antibodies were purchased from Sigma-Aldrich (Oakville, ON, USA). Anti-RSK1 and RSK2 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Invitrogen (Carlsbad, CA, USA), respectively. The phospho-RSK (Ser380) antibody was purchased from R&D Systems (Minneapolis, MN, USA). The phospho-4EBP1 Ser65 antibody was kindly provided by Dr Nahum Sonenberg (McGill University). All secondary horseradish peroxidase-conjugated antibodies used for immunoblotting were purchased from Chemicon (Temecula, CA, USA).
Immunoprecipitations, cap-binding assays and immunoblotting
Cell lysates were prepared as described elsewhere. 50 Briefly, cells were washed with ice-cold PBS and lysed in 10 mM K 3 PO 4 , 1 mM EDTA, 5 mM EGTA, 10 mM MgCl 2 , 50 mM b-glycerophosphate, 0.5% NP-40, 0.1% Brij 35, 0.1% deoxycholic acid, 1 mM sodium orthovanadate (Na 3 VO 4 ), 1 mM phenylmethylsulfonyl fluoride, and a complete protease inhibitor cocktail tablet (Roche, Indianapolis, IN, USA). For immunoprecipitations, cell lysates were incubated with the indicated antibody for 2 h, followed by 1 h of incubation with protein A-Sepharose CL-4B beads (GE Healthcare, Waukesha, WI, USA). For cap-binding assays, lysates were incubated with 7-methyl-GTP Sepharose (GE Healthcare) for 2 h. Immunoprecipitates were washed thrice in lysis buffer and eluted in reducing sample buffer. Eluates and total cell lysates were subjected to SDS-PAGE, and resolved proteins were transferred onto polyvinylidene difluoride membranes for immunoblotting.
Protein phosphotransferase assays 
RNA interference and viral infections
For siRNA-mediated knockdown of RSK1, RSK2, ERK1 and ERK2, validated 21-nucleotide cRNAs with symmetrical two nucleotide overhangs were obtained from Qiagen (Valencia, CA, USA). Colo829 cells were transfected using Oligofectamine (Invitrogen) and 50 nM siRNA per 35-mm dish. At 24 h following transfection, cells were serum-starved overnight before being collected. For short hairpin RNA (shRNA)-mediated knockdown, lentiviruses were produced using vectors from the Mission TRC shRNA library. Cells were infected in the presence of 4 mg/ml polybrene, and 2 days after viral infection, cells were treated and selected with 2 mg/ml puromycin. shRNA constructs were obtained from Sigma-Aldrich (shRSK1, TRCN470; shRSK2, TRCN537). Retroviruses were produced using the pBabe-puro vector to overexpress ectopic RasG12V, MEK1-DD or B-Raf-V600E mutants. Two days after infection, positive pools were selected in 2 mg/ml puromycin. Plasmids encoding HA-tagged RasG12V, B-Raf-V600E and flag-tagged MEK1-DD were previously described. 50 Protein synthesis measurements Cells were seeded in 6-well plates for 24 h, then serum-starved or maintained in low-serum (2%) medium for 16 to 18 h. After treatment with indicated inhibitors for 1 h, 0.5 mCi/ml [ 3 H]leucine was added to the medium. At indicated times of labelling, the medium was aspirated and the cells were incubated 30 min in cold 5% TCA. The wells were then washed once with 5% TCA and three times with tap water. The radioactivity incorporated into TCA-precipitable material was measured by liquid scintillation counting after solubilization in 0.1 M NaOH.
Polysomal fractionation and RNA extraction Sucrose density gradient centrifugation was employed to separate the subpolysomal from the polysomal ribosome fractions. Fifteen minutes before collection, 100 mg/ml cycloheximide was added to the culture medium. Cells were washed in ice-cold PBS supplemented with 100 mg/ml cycloheximide, and collected in polysome lysis buffer (PLB; 50 mm HEPES [pH 7.4], 250 mm KCl, 5 mm MgCl 2 , 250 mm sucrose, 1% Triton X-100, 1.3% sodium deoxycholate, 100 mg/ml cycloheximide, and protease inhibitors). Samples were incubated on ice for 15 min and then centrifuged at 10 000 g for 10 min at 4 1C. The resulting supernatant was layered on a 20-50% linear sucrose gradient (in PLB) and centrifuged in a SW40 rotor at 145 000 Â g for 165 min at 4 1C. Following centrifugation, the A 260 was continuously monitored and recorded using a Gradient Station IP (Biocomp, Fredericton, NB, USA) attached to a UV-MII (GE Healthcare) spectrophotometer. Polysomal fractions were collected and RNA was extracted using RNeasy Mini Kit (Qiagen). For RT-qPCR experiments, total RNA was extracted using the same procedure.
Quantitative real-time PCR and microarray experiments Total RNA was reverse-transcribed using the cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA) as described by the manufacturer. Gene expression levels of endogenous controls glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and beta-actin (ACTB) were determined using pre-validated Taqman Gene Expression Assays (Applied Biosystems), and gene expression level for RSK isoforms was determined using assays designed with the Universal Probe Library (UPL) from Roche. Microarray experiments were performed in triplicate using Nimblegen Human Gene Expression 4 Â 72 K Arrays according to the manufacturer's instructions (Roche NimbleGen, Madison, WI, USA). For each condition, 6.5 mg of polysomal or total RNA was reverse-transcribed and labelled RSK is required for mTORC1-dependent melanoma growth Y Romeo et al using Cy3 (Trilink Biotechnology, San Diego, CA, USA). The labelled material was then hybridized to the microarray overnight at 42 1C, washed and scanned at 5 mm resolution.
Microarray data analysis
Data was quantified and Robust Multichip Average-normalized using NimbleScan software (Roche). Normalized data was log2-transformed and analysed using Bioconductor packages and R statistical language. Using the R package limma, we fit linear models to identify genes regulated between different conditions. A batch effect term was added to the model to account for experimental bias and an interaction term allowed the identification of translational regulation independent of cytosolic mRNA level change. Genes having log2-coefficients smaller than À 0.58 (1.5-fold decrease) and P-value smaller than 0.05 were considered as significantly regulated. The replicate average log2-signals of genes downregulated in polysomal mRNA in the presence of mTOR and MAPK inhibitors were used as input for K-Means clustering using MeV Software. Enrichment analysis was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) and through the use of Ingenuity Pathways Analysis (Ingenuity Systems).
Proliferation and apoptosis assay
For proliferation assays, 2 Â 10 3 cells were seeded in 96-well plates. Cells were grown in the presence of inhibitors when indicated. The relative number of viable cells was measured every 24 h during 4 consecutive days using a nonradioactive cell proliferation assay from Promega (Madison, WI, USA). For cell counting, 5 Â 10 4 cells were seeded in 6-well plates and grown as described above. After 48 h, cells were stained with trypan blue and counted using a hemacytometer. Results displayed represent the mean of triplicates ± standard error (s.e.). For analysis of apoptotic cells, 3 Â 10 5 A375 cells were seeded in 35-mm dishes and grown in 10% FBS for 48 h. After trypsination, cells were washed twice with ice-cold PBS containing 5 mM CaCl 2 and incubated with PE labelled annexin V (BD Pharmingen, San Jose, CA, USA). Cells were washed twice and processed on a BD FACS Canto II cytometer.
Mouse xenotransplantation studies
All animals were housed under pathogen-free conditions, and experiments were performed in accordance with CCAC guidelines. Female Balb/c athymic nude mice (nu/nu) were purchased from Harlan (Montreal, Quebec, Canada) and used at 6-8 weeks of age. For subcutaneous tumour model studies, A375 or Colo829 cells stably expressing shRSK1 and shRSK2 were collected from sub-confluent cultures by brief exposure to 0.25% trypsin and 0.02% EDTA. The cells were washed once in PBS, and 2 Â 10 6 cells in a final volume of 200 ml were injected subcutaneously in the flanks of the mouse. The mice were monitored regularly and the tumours were measured every 2-3 days using a caliper.
